Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOSEMITE: Faricimab in Diabetic Macular Edema
NCT03622580Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2018
- Primary completion
- Oct 2020
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of faricimab in diabetic macular edema (DME), sponsored by Roche. Started Sep 2018; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03622580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03622580.